1. Market Research
  2. > Neurodegenerative Diseases - Pipeline Review, H2 2013

Neurodegenerative Diseases - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 275 pages

Neurodegenerative Diseases - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Neurodegenerative Diseases - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neurodegenerative Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurodegenerative Diseases. Neurodegenerative Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neurodegenerative Diseases.
- A review of the Neurodegenerative Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neurodegenerative Diseases pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Neurodegenerative Diseases.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neurodegenerative Diseases pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Neurodegenerative Diseases - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Neurodegenerative Diseases Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Neurodegenerative Diseases 13
Neurodegenerative Diseases Therapeutics under Development by Companies 15
Neurodegenerative Diseases Therapeutics under Investigation by Universities/Institutes 21
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Neurodegenerative Diseases Therapeutics - Products under Development by Companies 27
Neurodegenerative Diseases Therapeutics - Products under Investigation by Universities/Institutes 34
Companies Involved in Neurodegenerative Diseases Therapeutics Development 36
Bristol-Myers Squibb Company 36
F. Hoffmann-La Roche Ltd. 37
Biogen Idec Inc. 38
Apotex, Inc. 39
ExonHit Therapeutics SA 40
Isotechnika Pharma Inc. 41
EnVivo Pharmaceuticals 42
Les Laboratoires Servier 43
Pfizer Inc. 44
Merck KGaA 45
Addex Pharmaceuticals 46
Neuralstem, Inc. 47
Genfit 48
Nymox Pharmaceutical Corporation 49
ACADIA Pharmaceuticals Inc. 50
Yungjin Pharm Ind. Co., Ltd. 51
WhanIn Pharmaceutical Co., Ltd. 52
Suven Life Sciences Ltd. 53
MediPost Co., Ltd. 54
Newron Pharmaceuticals S.p.A. 55
Intas Pharmaceuticals Ltd. 56
Oryzon 57
Angelini Group 58
SCYNEXIS, Inc. 59
Chipscreen Biosciences Ltd 60
Quantum Pharmaceuticals 61
Oncodesign SA 62
Aegera Therapeutics Inc. 63
Medeia Therapeutics Ltd. 64
AngioChem Inc. 65
Phoenix Biotechnology, Inc. 66
Antyra, Inc. 67
TetraLogic Pharmaceuticals 68
NEURONAX 69
PsychoGenics, Inc. 70
GenKyoTex S.A. 71
Affichem 72
NeuroNascent, Inc. 73
Siena Biotech S.p.A. 74
NovaLead Pharma Pvt. Ltd. 75
N-Gene Research Laboratories, Inc. 76
BT PHARMA 77
Biovista Inc. 78
Nexgenix Pharmaceuticals, LLC 79
Proteostasis Therapeutics, Inc. 80
M's Science Corporation 81
Encore Therapeutics Inc. 82
Georgia Tech Research Corporation 83
MAKScientific, LLC 84
GENEXTRA S.p.A. 85
Ausio Pharmaceuticals, LLC 86
Histocell S.L. 87
Synthon BV 88
Varinel, Inc. 89
Sigmoid Pharma. 90
Neurodegenerative Diseases - Therapeutics Assessment 91
Assessment by Monotherapy Products 91
Assessment by Route of Administration 92
Assessment by Molecule Type 94
Drug Profiles 96
EVP-0334 - Drug Profile 96
G-15750 - Drug Profile 98
TGFTX-1 Program - Drug Profile 99
TGFTX-3 Program - Drug Profile 100
sarizotan hydrochloride - Drug Profile 101
CSO-240-0600 - Drug Profile 103
NeuroTrans Program - Drug Profile 104
NXD-5150 - Drug Profile 105
NNI-370 - Drug Profile 106
AF-243 - Drug Profile 107
Necrostatin Program - Drug Profile 108
AUS-131 - Drug Profile 109
EHT/AGN-0002 - Drug Profile 111
VAR-10300 - Drug Profile 112
EPO Mimetics - Drug Profile 114
MC-116 - Drug Profile 115
AMT-090 - Drug Profile 116
NXD-30001 - Drug Profile 117
VAR-10200 - Drug Profile 118
ponezumab - Drug Profile 119
ANG-3101 - Drug Profile 121
ANG-3201 - Drug Profile 122
GSK-3 Beta Inhibitor - Drug Profile 123
EHT/AGN-0003 - Drug Profile 124
Immunoglobulin - Drug Profile 125
NSI-189 - Drug Profile 126
NLP-61 - Drug Profile 128
YJP-60107 - Drug Profile 129
NST-0021 - Drug Profile 130
NST-0005 - Drug Profile 131
NST-0037 - Drug Profile 132
NG-094 - Drug Profile 133
FRP-XX - Drug Profile 134
AF-250s - Drug Profile 135
Alpha Synuclein Program - Drug Profile 136
TDP-43 Program - Drug Profile 137
NOX 2/1 Inhibitors - Drug Profile 138
diazoxide - Drug Profile 139
P2X7 Compounds - Drug Profile 141
TRKB PAM - Drug Profile 142
RPh-201 - Drug Profile 143
SUVN-501 - Drug Profile 145
SUVN-507 - Drug Profile 146
SUVN-901 - Drug Profile 147
SUVN-976 - Drug Profile 148
Drug Targeting Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 For Neuro Degenerative Diseases - Drug Profile 149
ER-Beta Program - Drug Profile 150
PT-00114 - Drug Profile 151
PT-00311 - Drug Profile 152
Glutaminyl Cyclase Inhibitors - Drug Profile 153
TDI-154 - Drug Profile 154
NST-0060 - Drug Profile 155
NPS-0155 - Drug Profile 156
FRP-924 - Drug Profile 157
NPT-002 - Drug Profile 158
PBI-04711 - Drug Profile 159
NT-KO-009 - Drug Profile 160
NT-KO-012 - Drug Profile 161
NT-CC-017 - Drug Profile 162
F-637 - Drug Profile 163
WIN-1001X - Drug Profile 164
RDC-5 - Drug Profile 165
Program-3 - Drug Profile 166
JRP-655 - Drug Profile 167
JRP-900 - Drug Profile 168
MAC-i Class I - Drug Profile 169
MAC-i Class II - Drug Profile 170
EAB-318 - Drug Profile 171
Drug Targeting HSP90 - Drug Profile 172
S-Allymercapto-N-Acetylcysteine - Drug Profile 173
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 174
CS-410 - Drug Profile 176
meldonium - Drug Profile 177
caffeic acid phenethyl ester - Drug Profile 178
TDI-185 - Drug Profile 179
Adenosine Antagonists - Drug Profile 180
Sphingosine Kinase-1 Inhibitor - Drug Profile 181
Sphingosine Kinase-2 Inhibitor - Drug Profile 182
miR-29b - Drug Profile 183
Estrogen Receptor Beta Ligand - Drug Profile 184
enreptin - Drug Profile 185
RE-024 - Drug Profile 186
Gamma-Secretase Modulators - Drug Profile 187
Retinal Neuroprotective Compounds - Drug Profile 188
Drug For Neuroprotection And Neurite-Promoting Activity - Drug Profile 189
mPTP Inhibitors - Drug Profile 190
BVA-202 - Drug Profile 191
BVA-203 - Drug Profile 192
UBP-608 - Drug Profile 193
VCE-006 - Drug Profile 194
CDNF Protein Therapy For Other Neurodegenerative Disease - Drug Profile 195
mGluR3 PAMs - Drug Profile 196
mGluR4 PAMs Backup Series - Drug Profile 197
mGluR4 PAMs Lead Series - Drug Profile 198
Drug For Tau-Related Diseases - Drug Profile 199
HAT Inhibitor Program - Drug Profile 200
Drugs For Neurodegenerative Diseases - Drug Profile 201
AM-5206 - Drug Profile 202
Alpha Synuclein - Drug Profile 204
MDA-107 - Drug Profile 205
MDA-107 Back Up - Drug Profile 207
Cyclohetero Cycloalkylaminoaryl Derivatives - Drug Profile 209
Drug For Neurodegenerative Disorders - Drug Profile 210
Drug 2 For Neurodegenerative Diseases - Drug Profile 211
Drug 1 For Neurodegenerative Diseases - Drug Profile 212
Glycolysis Inhibitors - Drug Profile 213
NS-640 - Drug Profile 214
ORY-2001 - Drug Profile 215
Biosimilar-2 - Drug Profile 216
Drug For Cancer And Neurodegenerative Disease - Drug Profile 217
LMW Immunomodulator - Drug Profile 218
Pluripotent Stem Cells From Embryonic Tissues - Drug Profile 219
HR-010 - Drug Profile 220
P7C3 - Drug Profile 221
Insulin-Regulated Amino Peptidase Inhibitor - Drug Profile 222
Secretory IgA - Drug Profile 223
Glutathione Peroxidase Mimetic Compounds - Drug Profile 224
Lipophilic Phenolic Antioxidants - Drug Profile 225
Tetraamine derivatives - Drug Profile 226
Aza-Peptide Epoxides - Drug Profile 227
PC-41 - Drug Profile 228
NST-0076 - Drug Profile 229
NST-0078 - Drug Profile 230
Salt-Inducible Kinase 2 Inhibitor - Drug Profile 231
Cell-Division Cycle Protein-Like Kinase Family Inhibitor - Drug Profile 232
GDNFOS Peptides - Drug Profile 233
Antibody Against GDNFOS3 - Drug Profile 234
Morphinans - Drug Profile 235
Opioid Peptides - Drug Profile 236
Tripeptide GGF - Drug Profile 237
Neurodegenerative Disease Program - Drug Profile 238
Compound-12 - Drug Profile 239
Compound-69 - Drug Profile 240
Compound-149 - Drug Profile 241
Drugs Targeting Leukocyte Immunoglobulin Like Receptor - Drug Profile 242
Compound-1 - Drug Profile 243
Compound-2 - Drug Profile 244
Neurodegenerative Diseases Therapeutics - Drug Profile Updates 245
Neurodegenerative Diseases Therapeutics - Discontinued Products 256
Neurodegenerative Diseases Therapeutics - Dormant Products 257
Neurodegenerative Diseases - Product Development Milestones 259
Featured News and Press Releases 259
Appendix 265
Methodology 265
Coverage 265
Secondary Research 265
Primary Research 265
Expert Panel Validation 265
Contact Us 266
Disclaimer 266



List of Tables

Number of Products Under Development for Neurodegenerative Diseases, H2 2013 22
Products under Development for Neurodegenerative Diseases - Comparative Analysis, H2 2013 23
Number of Products under Development by Companies, H2 2013 25
Number of Products under Development by Companies, H2 2013 (Contd..1) 26
Number of Products under Development by Companies, H2 2013 (Contd..2) 27
Number of Products under Development by Companies, H2 2013 (Contd..3) 28
Number of Products under Development by Companies, H2 2013 (Contd..4) 29
Number of Products under Investigation by Universities/Institutes, H2 2013 31
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 32
Comparative Analysis by Mid Clinical Stage Development, H2 2013 33
Comparative Analysis by Early Clinical Stage Development, H2 2013 34
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 35
Products under Development by Companies, H2 2013 36
Products under Development by Companies, H2 2013 (Contd..1) 37
Products under Development by Companies, H2 2013 (Contd..2) 38
Products under Development by Companies, H2 2013 (Contd..3) 39
Products under Development by Companies, H2 2013 (Contd..4) 40
Products under Development by Companies, H2 2013 (Contd..5) 41
Products under Development by Companies, H2 2013 (Contd..6) 42
Products under Investigation by Universities/Institutes, H2 2013 43
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 44
Bristol-Myers Squibb Company, H2 2013 45
F. Hoffmann-La Roche Ltd., H2 2013 46
Biogen Idec Inc., H2 2013 47
Apotex, Inc., H2 2013 48
ExonHit Therapeutics SA, H2 2013 49
Isotechnika Pharma Inc., H2 2013 50
EnVivo Pharmaceuticals, H2 2013 51
Les Laboratoires Servier, H2 2013 52
Pfizer Inc., H2 2013 53
Merck KGaA, H2 2013 54
Addex Pharmaceuticals, H2 2013 55
Neuralstem, Inc., H2 2013 56
Genfit, H2 2013 57
Nymox Pharmaceutical Corporation, H2 2013 58
ACADIA Pharmaceuticals Inc., H2 2013 59
Yungjin Pharm Ind. Co., Ltd., H2 2013 60
WhanIn Pharmaceutical Co., Ltd., H2 2013 61
Suven Life Sciences Ltd., H2 2013 62
MediPost Co., Ltd., H2 2013 63
Newron Pharmaceuticals S.p.A., H2 2013 64
Intas Pharmaceuticals Ltd., H2 2013 65
Oryzon, H2 2013 66
Angelini Group, H2 2013 67
SCYNEXIS, Inc., H2 2013 68
Chipscreen Biosciences Ltd, H2 2013 69
Quantum Pharmaceuticals, H2 2013 70
Oncodesign SA, H2 2013 71
Aegera Therapeutics Inc., H2 2013 72
Medeia Therapeutics Ltd., H2 2013 73
AngioChem Inc., H2 2013 74
Phoenix Biotechnology, Inc., H2 2013 75
Antyra, Inc., H2 2013 76
TetraLogic Pharmaceuticals, H2 2013 77
NEURONAX, H2 2013 78
PsychoGenics, Inc., H2 2013 79
GenKyoTex S.A., H2 2013 80
Affichem, H2 2013 81
NeuroNascent, Inc., H2 2013 82
Siena Biotech S.p.A., H2 2013 83
NovaLead Pharma Pvt. Ltd., H2 2013 84
N-Gene Research Laboratories, Inc., H2 2013 85
BT PHARMA, H2 2013 86
Biovista Inc., H2 2013 87
Nexgenix Pharmaceuticals, LLC, H2 2013 88
Proteostasis Therapeutics, Inc., H2 2013 89
M's Science Corporation, H2 2013 90
Encore Therapeutics Inc., H2 2013 91
Georgia Tech Research Corporation, H2 2013 92
MAKScientific, LLC, H2 2013 93
GENEXTRA S.p.A., H2 2013 94
Ausio Pharmaceuticals, LLC, H2 2013 95
Histocell S.L., H2 2013 96
Synthon BV, H2 2013 97
Varinel, Inc., H2 2013 98
Sigmoid Pharma., H2 2013 99
Assessment by Monotherapy Products, H2 2013 100
Assessment by Stage and Route of Administration, H2 2013 102
Assessment by Stage and Molecule Type, H2 2013 104
Neurodegenerative Diseases Therapeutics - Drug Profile Updates 254
Neurodegenerative Diseases Therapeutics - Discontinued Products 265
Neurodegenerative Diseases Therapeutics - Dormant Products 266
Neurodegenerative Diseases Therapeutics - Dormant Products (Contd..2) 267

List of Figures
Number of Products under Development for Neurodegenerative Diseases, H2 2013 22
Products under Development for Neurodegenerative Diseases - Comparative Analysis, H2 2013 23
Products under Development by Companies, H2 2013 24
Products under Investigation by Universities/Institutes, H2 2013 30
Mid Clinical Stage Products, H2 2013 33
Early Clinical Stage Products, H2 2013 34
Discovery and Pre-Clinical Stage Products, H2 2013 35
Assessment by Monotherapy Products, H2 2013 100
Assessment by Route of Administration, H2 2013 101
Assessment by Stage and Route of Administration, H2 2013 102
Assessment by Molecule Type, H2 2013 103
Assessment by Stage and Molecule Type, H2 2013 104



Companies Mentioned

Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Apotex, Inc.
ExonHit Therapeutics SA
Isotechnika Pharma Inc.
EnVivo Pharmaceuticals
Les Laboratoires Servier
Pfizer Inc.
Merck KGaA
Addex Pharmaceuticals
Neuralstem, Inc.
Genfit
Nymox Pharmaceutical Corporation
ACADIA Pharmaceuticals Inc.
Yungjin Pharm Ind. Co., Ltd.
WhanIn Pharmaceutical Co., Ltd.
Suven Life Sciences Ltd.
MediPost Co., Ltd.
Newron Pharmaceuticals S.p.A.
Intas Pharmaceuticals Ltd.
Oryzon
Angelini Group
SCYNEXIS, Inc.
Chipscreen Biosciences Ltd
Quantum Pharmaceuticals
Oncodesign SA
Aegera Therapeutics Inc.
Medeia Therapeutics Ltd.
AngioChem Inc.
Phoenix Biotechnology, Inc.
Antyra, Inc.
TetraLogic Pharmaceuticals
NEURONAX
PsychoGenics, Inc.
GenKyoTex S.A.
Affichem
NeuroNascent, Inc.
Siena Biotech S.p.A.
NovaLead Pharma Pvt. Ltd.
N-Gene Research Laboratories, Inc.
BT PHARMA
Biovista Inc.
Nexgenix Pharmaceuticals, LLC
Proteostasis Therapeutics, Inc.
M's Science Corporation
Encore Therapeutics Inc.
Georgia Tech Research Corporation
MAKScientific, LLC
GENEXTRA S.p.A.
Ausio Pharmaceuticals, LLC
Histocell S.L.
Synthon BV
Varinel, Inc.
Sigmoid Pharma.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.